Randomised trials in ovarian cancer: trial design considerations

被引:6
|
作者
Brady, MF
Thigpen, JT
Vermorken, JB
Parmar, MKB
机构
[1] Roswell Pk Canc Inst, GOG Stat Off, Buffalo, NY 14263 USA
[2] Univ Mississippi, Sch Med, Dept Med, Jackson, MS 39216 USA
[3] Univ Antwerp Hosp, Dept Med Oncol, Edegem, Belgium
[4] MRC, Canc Trials Off, Cambridge, England
关键词
end point selection; progression-free survival; response; survival; trial size;
D O I
10.1023/A:1008319704310
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Randomised clinical trials are considered the definitive source of evidence for guiding decisions in clinical practice. The concept of a clinical trial is based on sound scientific, ethical, and practical principles. The strength of evidence that an individual trial provides is assessed on the manner in which these principles are incorporated into the design and execution of the trial. Since the way these principles are incorporated into a trial is judgmental, the strength of evidence from an individual trial is a matter of degree. The purpose of this paper is to present some of the scientific, ethical and practical considerations surrounding the selection of endpoints and determination of sample size for trials in ovarian cancer.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [1] Exercise during CHemotherapy for Ovarian cancer (ECHO) trial: design and implementation of a randomised controlled trial
    Hayes, Sandra
    Obermair, Andreas
    Mileshkin, Linda
    Davis, Alison
    Gordon, Louisa G.
    Eakin, Elizabeth
    Janda, Monika
    Beesley, Vanessa L.
    Barnes, Elizabeth H.
    Spence, Rosalind Renee
    Sandler, Carolina
    Jones, Tamara
    Vagenas, Dimitrios
    Webb, Penny
    Andrews, John
    Brand, Alison
    Lee, Yeh Chen
    Friedlander, Michael
    Pumpa, Kate
    O'Neille, Helene
    Williams, Merran
    Stockler, Martin
    BMJ OPEN, 2023, 13 (04):
  • [2] No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials
    Abdel-Rahman, M. E.
    Butler, J.
    Sydes, M. R.
    Parmar, M. K. B.
    Gordon, E.
    Harper, P.
    Williams, C.
    Crook, A.
    Sandercock, J.
    Swart, A. M.
    Rachet, B.
    Coleman, M. P.
    BRITISH JOURNAL OF CANCER, 2014, 111 (03) : 589 - 597
  • [3] No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials
    M E Abdel-Rahman
    J Butler
    M R Sydes
    M K B Parmar
    E Gordon
    P Harper
    C Williams
    A Crook
    J Sandercock
    A M Swart
    B Rachet
    M P Coleman
    British Journal of Cancer, 2014, 111 : 589 - 597
  • [4] Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents
    Dranitsaris, George
    Cohen, Roger B.
    Acton, Gary
    Keltner, Llew
    Price, Melissa
    Amir, Eitan
    Podack, Eckhard R.
    Schreiber, Taylor H.
    JOURNAL OF IMMUNOTHERAPY, 2015, 38 (07) : 259 - 266
  • [5] Repurposed Drugs Trials for Ovarian Cancer
    DiFeo, Analisa
    CANCER JOURNAL, 2019, 25 (02) : 149 - 152
  • [6] Ten Important Considerations for Ovarian Cancer Screening
    Pavlik, Edward J.
    DIAGNOSTICS, 2017, 7 (02):
  • [7] Considerations in the Surgical Management of Ovarian Cancer in the Elderly
    Langstraat, Carrie
    Cliby, William A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (01) : 12 - 21
  • [8] Nintedanib and ovarian cancer: standardise surgery in trials?
    Kehoe, Sean
    LANCET ONCOLOGY, 2016, 17 (01) : 9 - +
  • [9] Design and Analysis of Cancer Clinical Trials for Personalized Medicine
    Jung, Sin-Ho
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (05):
  • [10] Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
    Kristina Lindemann
    Emma Gibbs
    Elisabeth Åvall-Lundqvist
    Rene dePont Christensen
    Kathrine Woie
    Marten Kalling
    Annika Auranen
    Seija Grenman
    Thomas Hoegberg
    Per Rosenberg
    Tone Skeie-Jensen
    Elisabet Hjerpe
    Anne Dørum
    Val Gebski
    Gunnar Kristensen
    British Journal of Cancer, 2017, 116 : 455 - 463